Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

NCT01177397 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

226

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Diffuse Large B-Cell Lymphoma
Glioblastoma Multiforme
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer
Neuroendocrine Tumors of Non-Pancreatic Origin
Hormone Receptor-Positive Breast Cancer

Interventions

DRUG: CC-223

Sponsor

Celgene